Tenax Therapeutics Inc [TENX] stock is trading at $9.47, up 0.74%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TENX shares have gain 29.37% over the last week, with a monthly amount glided 31.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tenax Therapeutics Inc [NASDAQ: TENX] stock has seen the most recent analyst activity on September 08, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $20. Previously, Leerink Partners started tracking the stock with Outperform rating on October 24, 2024, and set its price target to $16. On October 14, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $16 on the stock. William Blair started tracking the stock assigning a Outperform rating. Ladenburg Thalmann upgraded its rating to a Buy. MLV & Co started tracking with a Buy rating for this stock on December 16, 2014, and assigned it a price target of $7. In a note dated November 18, 2014, WallachBeth initiated an Buy rating and provided a target price of $12 on this stock.
Tenax Therapeutics Inc [TENX] stock has fluctuated between $4.63 and $9.60 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Tenax Therapeutics Inc [NASDAQ: TENX] shares were valued at $9.47 at the most recent close of the market. An investor can expect a potential return of 111.19% based on the average TENX price forecast.
Analyzing the TENX fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -25102.17%, Pretax Profit Margin comes in at -15741.24%, and Net Profit Margin reading is -15741.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.31 and Total Capital is -0.49.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.14 points at the first support level, and at 8.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.75, and for the 2nd resistance point, it is at 10.03.
Ratios To Look Out For
For context, Tenax Therapeutics Inc’s Current Ratio is 15.58. In addition, the Quick Ratio stands at 15.58 and the Cash Ratio stands at 41.73.
Transactions by insiders
Recent insider trading involved Giordano Christopher Thomas, CEO, that happened on Nov 18 ’25 when 1612.0 shares were purchased. CEO, Giordano Christopher Thomas completed a deal on Nov 20 ’25 to buy 538.0 shares. Meanwhile, CEO Giordano Christopher Thomas bought 455.0 shares on Nov 19 ’25.
